Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 5/20 | 0.44 |
| ▸ | RXRB | P28702 | 5/20 | 0.44 |
| ▸ | RXRG | P48443 | 4/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596863 | 0.90 | TTR (0.43) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL4897531 | 0.84 | TTR (0.39) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL16959467 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL29269101 | 0.77 | TDP1 (0.50) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL25353990 | 0.75 | ALDH1A1 (0.45) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL4596164 | 0.75 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL4596487 | 0.75 | TDP1 (0.41) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL11208124 | 0.75 | MEN1 (0.47) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL258621 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRTDP1HPGD | |
| SCHEMBL4596621 | 0.73 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4476222-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | RXFP3, RXFP4, RXFP2 | ALDH1A1 4818/4885CYP3A4 3694/4885TSHR 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.